National Institute Of Gastroenterology Saverio De Bellis Research Hospital
- Address
- lock Available on a paid plan
Analytical, Diagnostic and Therapeutic Techniques and Equipment
The National Institute Of Gastroenterology Saverio De Bellis Research Hospital is advancing innovative therapeutic platforms, focusing on safety and efficacy of new biologics and targeted agents for gastrointestinal conditions.
- Combination biologic regimens for inflammatory bowel disease
- Biomarker‑driven selection of anti‑EGFR and anti‑VEGF therapies
- Evaluation of novel oral small molecules in chronic liver disease
- Integration of imaging biomarkers to monitor treatment response
These efforts aim to improve patient outcomes by refining diagnostic tools and delivering more precise, patient‑centered treatments.
Digestive System Diseases
Research at the site targets major disorders of the gastrointestinal tract, including cancers of the colon, stomach, and esophagus, as well as biliary tract malignancies.
- First‑line strategies for metastatic colorectal cancer
- Targeted therapy for FGFR2b‑positive gastric cancer
- Therapeutic options for unresectable esophageal squamous cell carcinoma
- Clinical evaluation of novel agents in biliary tract cancer
The goal is to identify regimens that extend survival and preserve quality of life for patients with these serious conditions.
Immune System Diseases
The institute conducts extensive trials on chronic inflammatory diseases of the gut and liver, seeking safer and more effective immune‑modulating therapies.
- Long‑term safety of oral ozanimod in Crohn’s disease
- Combination of mirikizumab with metabolic agents for ulcerative colitis and obesity
- Evaluation of seladelpar in primary biliary cholangitis
- Novel biologics for moderate to severe ulcerative colitis
These studies aim to achieve durable remission while minimizing adverse effects, offering new hope for patients with immune‑mediated gastrointestinal disorders.
Neoplasms
A broad oncology program addresses solid tumors that affect the digestive and related systems, emphasizing precision medicine and novel antibody‑drug conjugates.
- Antibody‑drug conjugate efficacy in advanced esophageal cancer
- KRAS G12C‑targeted therapy in metastatic colorectal cancer
- Combination immunotherapy with avelumab and cetuximab
- Biomarker‑guided cetuximab strategies across multiple treatment lines
By integrating molecular profiling, the site strives to personalize treatment and improve overall survival for patients with these aggressive neoplasms.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 48 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 47 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 13 by active trials.
lock +12 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in National Institute Of Gastroenterology Saverio De Bellis Research Hospital
lock Showing 1 of 27 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol to Evaluate the Efficacy and Safety of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease | Janssen Cilag International | Phase IV | Recruiting | Dec 2025 | — |
IMP list
lock Showing 1 of 48 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bevacizumab | 8 | Unknown | 2021-07-01 | 2026-03-30 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.